|
- Industry veteran in global operations and partnerships to spearhead international expansion
- Operational transformation underway to elevate the brand's standing in derma beauty
SEOUL, South Korea, Feb. 26, 2026 /PRNewswire/ -- MEDIPEEL, majority-owned by Morgan Stanley Private Equity Asia, has announced the appointment of Jason Wi as its new Chief Executive Officer. Under Wi's leadership, the company has launched a comprehensive restructuring of its global operations, aimed at building a resilient and scalable operating model to support sustained international growth.
Wi brings an extensive background in strategic consulting and investment, having served at McKinsey & Company and SoftBank Ventures Asia. His career is marked by a proven track record in scaling high-growth platform companies and leading the overseas expansion of various K-culture ventures. MEDIPEEL intends to leverage Wi's deep expertise and global network to accelerate its transition into a dominant player in the global beauty market.
As part of its refined strategy, MEDIPEEL is shifting its international focus from a traditional, export-heavy model toward a localized, partnership-driven approach. This transition is designed to create a more structured and agile operating system. Simultaneously, the company will reinforce its core identity as an "efficacy-focused derma beauty" brand, ensuring it remains competitive in sophisticated international markets. Supported by Morgan Stanley PE's global resources and Wi's operational acumen, MEDIPEEL is poised to establish a durable framework capable of navigating volatile market conditions.
Furthermore, Wi plans to integrate AI and data-driven operational methodologies—honed during his time in the platform industry—into MEDIPEEL's core business. Key initiatives will include optimizing supply chain management and enhancing customer engagement to drive long-term operational efficiency and long-term returns.
"The sustainable success of K-beauty brands on the global stage depends on two critical pillars: a distinctive brand heritage and an institutionalized operating system that can sustain it," said CEO Jason Wi. "We will focus on strengthening strategic global alliances while elevating our internal standards to transform MEDIPEEL into a world-class, trusted beauty platform."
MEDIPEEL is the flagship brand of SKINIDEA, which is under MDP Holdings, a portfolio company of Morgan Stanley PE Asia. SKINIDEA is recognized for its innovative products that integrate premium ingredients and patented dermatological technology. Exporting to more than 75 countries, SKINIDEA develops high-performance skincare solutions through comprehensive research and clinical trials, ensuring both instant and long-lasting improvements tailored to various skin types.
- Industry veteran in global operations and partnerships to spearhead international expansion
- Operational transformation underway to elevate the brand's standing in derma beauty
SEOUL, South Korea, Feb. 26, 2026 /PRNewswire/ -- MEDIPEEL, majority-owned by Morgan Stanley Private Equity Asia, has announced the appointment of Jason Wi as its new Chief Executive Officer. Under Wi's leadership, the company has launched a comprehensive restructuring of its global operations, aimed at building a resilient and scalable operating model to support sustained international growth.
Wi brings an extensive background in strategic consulting and investment, having served at McKinsey & Company and SoftBank Ventures Asia. His career is marked by a proven track record in scaling high-growth platform companies and leading the overseas expansion of various K-culture ventures. MEDIPEEL intends to leverage Wi's deep expertise and global network to accelerate its transition into a dominant player in the global beauty market.
As part of its refined strategy, MEDIPEEL is shifting its international focus from a traditional, export-heavy model toward a localized, partnership-driven approach. This transition is designed to create a more structured and agile operating system. Simultaneously, the company will reinforce its core identity as an "efficacy-focused derma beauty" brand, ensuring it remains competitive in sophisticated international markets. Supported by Morgan Stanley PE's global resources and Wi's operational acumen, MEDIPEEL is poised to establish a durable framework capable of navigating volatile market conditions.
Furthermore, Wi plans to integrate AI and data-driven operational methodologies—honed during his time in the platform industry—into MEDIPEEL's core business. Key initiatives will include optimizing supply chain management and enhancing customer engagement to drive long-term operational efficiency and long-term returns.
"The sustainable success of K-beauty brands on the global stage depends on two critical pillars: a distinctive brand heritage and an institutionalized operating system that can sustain it," said CEO Jason Wi. "We will focus on strengthening strategic global alliances while elevating our internal standards to transform MEDIPEEL into a world-class, trusted beauty platform."
MEDIPEEL is the flagship brand of SKINIDEA, which is under MDP Holdings, a portfolio company of Morgan Stanley PE Asia. SKINIDEA is recognized for its innovative products that integrate premium ingredients and patented dermatological technology. Exporting to more than 75 countries, SKINIDEA develops high-performance skincare solutions through comprehensive research and clinical trials, ensuring both instant and long-lasting improvements tailored to various skin types.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
MEDIPEEL Appoints Jason Wi as CEO to Drive Global Operational Excellence and Strategic Growth
|
JAKARTA, Indonesia, Feb. 26, 2026 /PRNewswire/ -- Kerry's BC30™ (Bacillus coagulans GBI‑30, 6086), a resilient, spore‑forming probiotic ingredient, has received regulatory approval in Indonesia for use with the "Live Culture" claim across applicable general food categories. The approval follows the inclusion of BC30™ in Indonesia's permitted microorganism list under PERBPOM No. 38/2023, which defines the microorganisms permitted for use in processed foods in Indonesia.
Products containing BC30™ may communicate "Live Culture" on pack and in marketing communications, in full compliance with Indonesia's National Agency of Drug and Food Control (BPOM) requirements. The approval applies to general food categories, excluding Category 13.0 – Special Nutrition Products, which are regulated separately under Indonesia's food category framework.
"This approval represents an important step forward for manufacturers looking to develop credible, compliant functional foods in Indonesia," said Olivier De Salmiech, Vice President, Health & Therapies, Kerry Asia Pacific, Middle East & Africa. "Being able to communicate a 'Live Culture' claim with BC30™ provides new opportunities to meet consumer interest in digestive health, while maintaining the formulation stability and quality required for food and beverage applications."
Kerry's consumer research shows that digestive health has become the number one functional health need globally, with 76% of consumers believing gut health affects overall health and wellbeing. Across Southeast Asia, consumers increasingly seek functional foods and beverages that support everyday digestive wellbeing.
Designed for food and beverage applications, BC30™ (Bacillus coagulans GBI‑30, 6086) is known for its ability to remain viable through manufacturing, storage, and digestion, helping deliver live cultures to the gut.
To qualify for the "Live Culture" claim in Indonesia, products containing BC30™ must meet several key regulatory conditions. These include the declaration of the full genus, species, and strain name: Bacillus coagulans GBI‑30, 6086, in the ingredient statement. Finished products must deliver a minimum of 1 × 10⁶ CFU per gram or millilitre at the end of shelf life, supported by appropriate analytical data. In addition, clear storage instructions must be stated on finished goods to ensure compliance with BPOM requirements.
The approval of BC30™ supports Kerry's ongoing commitment to enabling science‑based, compliant innovation in functional foods and beverages tailored to local market needs.
JAKARTA, Indonesia, Feb. 26, 2026 /PRNewswire/ -- Kerry's BC30™ (Bacillus coagulans GBI‑30, 6086), a resilient, spore‑forming probiotic ingredient, has received regulatory approval in Indonesia for use with the "Live Culture" claim across applicable general food categories. The approval follows the inclusion of BC30™ in Indonesia's permitted microorganism list under PERBPOM No. 38/2023, which defines the microorganisms permitted for use in processed foods in Indonesia.
Products containing BC30™ may communicate "Live Culture" on pack and in marketing communications, in full compliance with Indonesia's National Agency of Drug and Food Control (BPOM) requirements. The approval applies to general food categories, excluding Category 13.0 – Special Nutrition Products, which are regulated separately under Indonesia's food category framework.
"This approval represents an important step forward for manufacturers looking to develop credible, compliant functional foods in Indonesia," said Olivier De Salmiech, Vice President, Health & Therapies, Kerry Asia Pacific, Middle East & Africa. "Being able to communicate a 'Live Culture' claim with BC30™ provides new opportunities to meet consumer interest in digestive health, while maintaining the formulation stability and quality required for food and beverage applications."
Kerry's consumer research shows that digestive health has become the number one functional health need globally, with 76% of consumers believing gut health affects overall health and wellbeing. Across Southeast Asia, consumers increasingly seek functional foods and beverages that support everyday digestive wellbeing.
Designed for food and beverage applications, BC30™ (Bacillus coagulans GBI‑30, 6086) is known for its ability to remain viable through manufacturing, storage, and digestion, helping deliver live cultures to the gut.
To qualify for the "Live Culture" claim in Indonesia, products containing BC30™ must meet several key regulatory conditions. These include the declaration of the full genus, species, and strain name: Bacillus coagulans GBI‑30, 6086, in the ingredient statement. Finished products must deliver a minimum of 1 × 10⁶ CFU per gram or millilitre at the end of shelf life, supported by appropriate analytical data. In addition, clear storage instructions must be stated on finished goods to ensure compliance with BPOM requirements.
The approval of BC30™ supports Kerry's ongoing commitment to enabling science‑based, compliant innovation in functional foods and beverages tailored to local market needs.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
BC30™ Approved for "Live Culture" Claim in Indonesia, Opening Opportunities in F&B Innovation
